

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/7672869>

Functional Interactions of Raf and MEK with Jun-N-Terminal Kinase (JNK) Result in a Positive Feedback Loop on the Oncogenic Ras Signaling Pathway †

ARTICLE *in* BIOCHEMISTRY · SEPTEMBER 2005

Impact Factor: 3.02 · DOI: 10.1021/bi050619j · Source: PubMed

CITATIONS

23

READS

13

12 AUTHORS, INCLUDING:



Hsiang-Fu Kung

The Chinese University of Hong Kong

290 PUBLICATIONS 8,313 CITATIONS

[SEE PROFILE](#)



Fred Friedman

National Institute of Mental Health (NIMH)

123 PUBLICATIONS 2,350 CITATIONS

[SEE PROFILE](#)



Mohamed Boutjdir

State University of New York Downstate Medi...

97 PUBLICATIONS 2,230 CITATIONS

[SEE PROFILE](#)



Matthew Pincus

University at Albany, The State University of ...

192 PUBLICATIONS 4,953 CITATIONS

[SEE PROFILE](#)

Author Guidelines

(Revised May 2015)

Contents (click on the topic)

Objectives of the Journal | Editorial Organization and Reviewing Process | Submission of Manuscripts – Submission | **Electronic Manuscript Preparation | Manuscript Types** – Rapid Reports – Accelerated Publications – New Concepts – Current Topics – Additions/Corrections
Assembly/Preparation of Manuscripts – Manuscript Assembly – Illustration Preparation – Title Page – Abbreviations – Abstract – Introduction – Experimental Procedures (Materials and Methods) – Hazardous Procedures – Results – Kinetic and Equilibrium Data – Protein Sequence Data – Structural Data – Other Databases – Discussion – Acknowledgment – Appendix – References – Tables – Structures, Charts, and Schemes – Figure Legends – Figures – Graphic for the Table of Contents – Supporting Information | **Accepted Papers** – Proofs – ACS Policies for E-Prints and Reprints

OBJECTIVES OF THE JOURNAL

The purpose of *Biochemistry* is to publish the results of original research that contribute significantly to the understanding of the mechanism of biological phenomena in terms of molecular structure and/or function. Preference will be accorded to manuscripts that develop new concepts or experimental approaches, particularly in the advancing areas of biochemical science. Manuscripts that are primarily theoretical in nature or in the field of bioinformatics must be directed toward explaining important results previously not understood, making important predictions that can be experimentally tested, or developing significant advances in theory of general interest to biochemists. Submission of manuscripts in emerging areas in chemical biology, biophysics, proteomics, model studies and structures, cellular and molecular biology, computational chemistry, and new methods development is encouraged especially if they address basic biochemical mechanisms. Publication of preliminary or inconclusive results is discouraged, as is the simultaneous publication of manuscripts of overlapping content. Submission of a manuscript to *Biochemistry* implies that the same work has not been published nor is under consideration for publication elsewhere. This policy also applies to material submitted for publication in an electronic database system of a public nature, which we consider to constitute prior publication. In addition, no legal restrictions must exist, e.g., those associated with the filing of patents.

In addition to regular research reports, *Biochemistry* publishes four types of special articles: Rapid Reports, Accelerated Publications, New Concepts, and Current Topics. These are described below in detail.

EDITORIAL ORGANIZATION AND REVIEWING PROCESS

The Editor is appointed by the American Chemical Society and has the final responsibility for all editorial decisions. Associate Editors, together with the Editor, process all manuscripts received. Members of the Editorial Advisory Board are usually appointed for a three-year term and may be reappointed.

When a manuscript is received, the Editors first judge whether its content falls within the scope of *Biochemistry*. Manuscripts that are primarily descriptive, confirmative of previous work, of a highly specialized nature, or that do not address fundamental biochemical questions or, in the judgment of the Editors, are not of sufficient interest to the general readers of *Biochemistry* will be returned to the author without a formal written review. These decisions are reached with the participation of at least two Editors or an Editor and an Editorial Advisory Board member and should be considered final. After this preliminary review, manuscripts are sent to at least two independent reviewers for evaluation. Reviewers are selected for their competence in specialized areas of biochemistry from a database of qualified specialists. They are expected to disqualify themselves if they have a conflict of interest, such as association with the author's laboratory or preconceived opinions about the work. Authors are required to recommend four qualified reviewers other than members of the Advisory Board. Authors should take care not to recommend reviewers that have a real or perceived conflict of interest (e.g., a collaborator or someone who has recently published with one of the authors). Authors may also request that certain (but not more than three) reviewers not be chosen. Any request to exclude a reviewer must be accompanied by an explanation in the cover letter. Members of the Editorial Advisory Board cannot be disqualified from participating in the final disposition of a manuscript. The reviewers are advisory to the Editor, and their reports are used to reach the editorial decision. If the reviewers disagree, or if in the judgment of the Editor the manuscript has not received adequate consideration, the manuscript and the reviewers' opinions are submitted to a member of the Editorial Advisory Board for arbitration. Editorial decisions that result from this process are usually final. Reviews will normally be sent to authors by e-mail unless the authors request otherwise.

When a manuscript is returned to the author for revision, the author should reply to the specific recommendations of the reviewers and in an accompanying letter indicate those recommendations that have been incorporated into the revision and the reasons any have been disregarded. Usually only one major revision will be considered.

Handwritten corrections will not be accepted. The revised manuscript should be returned to the assigned Editorial Office within 60 days. **A revised manuscript received beyond the 60-day period will be considered as a new submission, will receive a new number, and usually will undergo a new review process.**

JUST ACCEPTED MANUSCRIPTS

Just Accepted manuscripts are peer-reviewed, accepted manuscripts that are posted on the ACS Publications website prior to technical editing, formatting for publication, and author proofing—usually within 30 minutes to 24 hours of acceptance by the editorial office. During the manuscript submission process, Authors can choose to have their manuscript posted online as a *Just Accepted* manuscript. They should take this choice

into account when planning intellectual and patent activities related to a manuscript. To ensure rapid delivery of the accepted manuscript to the Web, Authors must adhere carefully to all requirements in the journal's Author Guidelines. For further information, please refer to the *Just Accepted* FAQ, at <http://services.acs.org/pubshelp/passthru.cgi?action=kb&item=244>. Note that publishing a manuscript as *Just Accepted* is not a means by which to comply with the [NIH Public Access Mandate](#).

ASAP Publication. Accepted manuscripts will be published on the “Articles ASAP” page on the Journal Web site as soon as page proofs are corrected and all author concerns are resolved. Publication on the Web usually occurs within three working days of receipt of page proof corrections, and this can be anywhere from two to four weeks in advance of the cover date of the issue. Authors who do not choose the *Just Accepted* option should take the ASAP schedule into account when planning intellectual and patent activities related to a manuscript. The actual date on which an accepted paper is published on the Web is recorded on the Web version of the manuscript and on the first page of the PDF version.

SUBMISSION OF MANUSCRIPTS

Authors should submit manuscripts through the ACS website. Mailed (hard-copy) submissions are discouraged and will only be considered after the author has obtained prior permission of the Editor. E-mailed submissions will not be processed.

Authors should review Assembly/Preparation of Manuscripts prior to submission of a manuscript. Close attention to all the required details discussed in Assembly/Preparation of Manuscripts will expedite review and reduce the time to publication.

Journal Publishing Agreement. A properly completed and signed Journal Publishing Agreement must be submitted for each manuscript. ACS Paragon Plus provides an electronic version of the Agreement that will be available on the **My Authoring Activity** tab of the Corresponding Author's Home page once the manuscript has been assigned to an Editor. A PDF version of the Agreement is also available, but **Authors are strongly encouraged to use the electronic Journal Publishing Agreement**. If the PDF version is used, **all pages of the signed PDF Agreement must be submitted**. If the Corresponding Author cannot or should not complete either the electronic or PDF version for any reason, another Author should complete and sign the PDF version of the form. Forms and complete instructions are available at <http://pubs.acs.org/page/copyright/journals/index.html>.

Conflict of Interest Disclosure. A statement describing any financial conflicts of interest or lack thereof is published with each manuscript. During the submission process, the corresponding author must provide this statement on behalf of all authors of the manuscript. The statement should describe all potential sources of bias, including affiliations, funding sources, and financial or management relationships, that may constitute conflicts of interest (please see the [ACS Ethical Guidelines](#)). The statement will be published in the final article. If no conflict of interest is declared, the following

statement will be published in the article: “The authors declare no competing financial interest.”

Professional Ethics. In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses CrossCheck's iThenticate software to screen submitted manuscripts for similarity to published material. Note that your manuscript may be screened during the submission process. Further information about plagiarism can be found in Part B of the [Ethical Guidelines to Publication of Chemical Research](#).

Author List. During manuscript submission, the submitting author must provide contact information (full name, email address, institutional affiliation and mailing address) for all of the co-authors. Because all of the author names are automatically imported into the electronic Journal Publishing Agreement, the names must be entered into ACS Paragon Plus in the same sequence as they appear on the first page of the manuscript. (Note that co-authors are not required to register in ACS Paragon Plus.) The author who submits the manuscript for publication accepts the responsibility of notifying all co-authors that the manuscript is being submitted. Deletion of an author after the manuscript has been submitted requires a confirming letter to the Editor-in-Chief from the author whose name is being deleted. For more information on ethical responsibilities of authors, see the [Ethical Guidelines to Publication of Chemical Research](#).

ORCID. All authors are encouraged to register for an ORCID iD, a unique researcher identifier. With this standard identifier, you can create a profile of your research activities to distinguish yourself from other researchers with similar names and make it easier for your colleagues to find your publications. Learn more at <http://www.orcid.org>.

Authors and reviewers can add their ORCID iD to, or register for an ORCID iD from, their account in ACS Paragon Plus. Submitting authors have the option to provide existing ORCID iDs for co-authors during submission, but they cannot create new ORCID iDs for co-authors.

Assistance with English Language Editing. Authors may want to have their manuscripts edited professionally before submission to improve clarity. The ACS ChemWorx English Editing Service can assist you in improving and polishing the language in your manuscript. You can learn more about the services offered, at <http://es.acschemworx.acs.org>.

Submission

Manuscripts must be submitted via the ACS Paragon Plus Environment (<http://paragonplus.acs.org/login>). Complete instructions and an overview of the electronic online (Web) submission process are available through the secure ACS Paragon Plus Web site. Authors must also submit all revisions of manuscripts via the ACS Paragon Plus Environment. The web submission site employs state-of-the-art security mechanisms to ensure that all electronically submitted papers are secure. These same security mechanisms are also utilized throughout the peer-review process, permitting access only to editors and reviewers who are assigned to a particular paper.

All manuscript submissions should also include a submittal letter (cover letter) with a brief description of the interest of the article to the readership of *Biochemistry*.

Any materials that cannot be supplied electronically should be addressed to

Richard N. Armstrong
Vanderbilt University School of Medicine
Department of Biochemistry
832 RRB, 23rd Avenue South at Pierce
Nashville, TN 37232-0146

Electronic manuscript templates are available in several word-processing versions at the *Biochemistry* homepage. Authors are encouraged to use the templates provided. Rapid Reports are strictly limited to four printed journal pages and **must** be submitted on the template for Rapid Reports

(http://pubs.acs.org/page/bichaw/submission/bichaw_templates.html).

ELECTRONIC MANUSCRIPT PREPARATION

The final accepted version of the manuscript must be submitted in electronic form. Manuscripts prepared with the software packages listed below will be used for production, providing the following guidelines are adhered to. Failure to adhere to the following instructions may cause delays in publication.

When preparing a manuscript, use the document mode or its equivalent in the word-processing program; i.e., do not save files in "Text Only" (ASCII) mode. If a non-Western version of the word-processing software was used to prepare the manuscript, save the file in rich-text format (RTF). Do not include any page-layout instructions such as placement information for graphics in the file. The text should be left justified, and automatic end-of-line hyphenation should be turned off. Use carriage returns only to end headings and paragraphs, not to break lines of text. Do not insert spaces before punctuation. References must conform to the format described herein. Ensure that all characters are correctly represented throughout the manuscript: for example, 1 (one) and l (ell), 0 (zero) and O (oh), x (ex) and × (times sign). Check the final version carefully for consistent notation and correct spelling. The Journal Publications office conversion program will faithfully translate any errors to the typeset copy.

All text (including the title page, abstract, all sections of the body of the paper, figure captions, scheme or chart titles and footnotes, and references) and tabular material should be in one file. It is best to use the fonts "Times" and "Symbol." Other fonts, particularly those that do not come bundled with the system software, may not translate properly. Ensure that all special characters (e.g., Greek characters, math symbols, etc.) are present in the body of the text as characters and not as graphic representations. Consult the documentation for the specific software package being used on how to detect the presence of graphics in the files, and replace them with the appropriate text characters.

Tables may be created using a word processor's text mode or table-format feature. The table-format feature is preferred. Ensure each data entry is in its own table cell. If the

text mode is used, separate columns with a single tab and use a line feed (return) at the end of each row.

Please find a list of acceptable word processing packages at <http://pubs.acs.org/paragonplus/submission/general/software.html>.

Preparing and Submitting Manuscripts Using TeX/LaTeX

Authors who submit manuscripts composed in TeX/LaTeX should submit a PDF file of the manuscript along with the native TeX/LaTeX manuscript package as a ZIP Archive. Use of the freely available **achemso style package** to help prepare your submission is strongly encouraged. The achemso package provides the official macros (achemso.cls) and BibTeX styles (achemso.bst and biochem.bst) for submission to ACS journals. The package and instructions are available from [CTAN, the Comprehensive TeX Archive Network](#). For complete information on submitting TeX/LaTeX files, see [Preparing and Submitting Manuscripts Using TeX/LaTeX](#).

MANUSCRIPT TYPES

There are six manuscript types. When submitting a manuscript through the electronic submission process, the submitting agent selects the appropriate manuscript type from a pull-down menu. The majority of manuscripts will naturally be considered as Regular Articles. Other more specialized manuscript types are Rapid Reports, Accelerated Publications, New Concepts, Current Topics, and Additions/Corrections. Descriptions of these manuscript types follow.

RAPID REPORTS

The *Biochemistry* Rapid Report is a short manuscript type reserved for timely topics of unusual interest. The journal will make every effort to return an initial decision with three weeks of receipt. These Rapid Reports will be strictly limited to four printed pages. Authors are asked to adhere to the following guidelines when submitting a Rapid Report. Manuscripts that do not adhere to these rules will be placed in the standard *Biochemistry* Article workflow. **Use of the appropriate template is mandatory for submission of Rapid Reports.**

Preparation of Rapid Reports

- Title, authors, and affiliations. Provide complete contact information for the corresponding author, including a phone number and an email address.
- Abstract (no more than 100 words)
- Main Text
 - Includes an introduction, a brief description of experimental procedures, and the results and discussion in one combined block of text (no headings for subsections)
 - Display Items such as tables, structures, charts, schemes, figures, and figure legends should be embedded in the Main Text.

- Detailed Experimental Procedures should be included in the Supporting Information. These methods should be described in sufficient detail to enable others to repeat the experiment.
- Acknowledgments (in-line heading)
- References. Note that for Rapid Reports the inclusion of complete titles for the references is optional; however, complete titles should be included if space permits.
- Graphic for the Table of Contents (on a separate page)
- Supporting Information (as a separate file)

General Considerations

All other manuscript specifications and journal requirements remain as described for *Biochemistry* Articles as described herein.

ACCELERATED PUBLICATIONS

Manuscripts given the status of Accelerated Publications must deal with experimental results of unusual and timely significance and be of interest to the general reader of *Biochemistry*. Such manuscripts must contain all elements of a regular manuscript and satisfy the usual criteria governing the publication of papers in *Biochemistry*.

Additional criteria for accelerated status:

- The manuscript must be accompanied by a transmittal letter justifying the reasons why the author(s) believes the work should receive accelerated publication status.
- The transmittal letter should include the names of at least four knowledgeable scientists who are qualified to act as impartial reviewers.

Every effort will be made to expedite the review of such manuscripts. It is intended that these papers be published within two months of acceptance. Galley proofs of papers accepted for accelerated publication must be returned to Journal Publications within 24 hours. Questions regarding the suitability of manuscripts for accelerated publication should be addressed to the Editor in writing.

NEW CONCEPTS

New ideas, original models, imaginative correlation of data, and controversy all contribute to the progress of science. In order to provide a venue for new concepts and productive scientific discourse, *Biochemistry* will publish short articles that represent personal views and new ideas about important areas of biochemistry. In areas where controversy exists, opposing views will be published. Both solicited and unsolicited contributions will be considered for New Concepts.

CURRENT TOPICS

Current Topics are intended to familiarize the general reader with the current knowledge in a biochemical field or a topic of particular interest. Authorship usually is by invitation,

but the Editors welcome suggestions of topics and authors. Topics that have been recently reviewed in other journals will not be considered.

Manuscripts should adhere to the general format of regular papers published in this Journal but do not require the subheadings of experimental papers. Manuscripts will be reviewed for content, accuracy, and clarity. It is intended that accepted manuscripts be published within two months of acceptance. They will appear in the front of an issue.

ADDITIONS/CORRECTIONS

Additions and Corrections may be used to address important issues or correct errors and omissions of consequence that arise after publication of an article. Additions and Corrections may be requested by the author(s) or initiated by the Editor after discussions with the corresponding author. Readers who detect errors of consequence in the work of others should contact the corresponding author of that work. All Additions and Corrections are subject to approval by the Editor, and minor corrections and additions will not be published. Additions and Corrections from authors should be submitted via the ACS Paragon Plus environment by the corresponding author for publication in the "Addition/Correction" section of the Journal. The corresponding author should obtain approval from all of the article co-authors prior to submitting an Addition and Correction or provide evidence that such approval has been solicited. The Addition and Correction should include the original article title and author list, citation including DOI, and details of the correction. For proper formatting, see examples in a current issue of the Journal.

RETRACTIONS

Articles may be retracted for scientific or ethical reasons. Articles that contain seriously flawed or erroneous data such that their findings and conclusions cannot be relied upon may be retracted in order to correct the scientific record. Retractions may be requested by the article author(s) or by the journal Editor(s) but are ultimately published at the discretion of the Editor. When an article is retracted, a notice of Retraction will be published containing information about the original article title, author list, and the reason for the Retraction. Retracted articles will be accompanied by the related Retraction notice and will be marked as "Retracted". The originally published article will remain on the web except in extraordinary circumstances (e.g. where deemed legally necessary, or if the availability of the published content poses a public health risk). The American Chemical Society follows guidance from the Committee on Publication Ethics (COPE) when considering retractions; for more information see <http://publicationethics.org/>.

ASSEMBLY/PREPARATION OF MANUSCRIPTS

Manuscripts should be written in clear, concise English. Editors, reviewers, and readers may tend to be biased against results reported in complex or excessively verbose language. Regular research Articles should include section headings.

Manuscript Assembly: Structures, charts, schemes, figures, and figure legends may be embedded in the text or should appear as indicated below.

- Title Page
- Abbreviations and Textual Footnotes
- Abstract
- Introduction (no heading)
- Experimental Procedures (Materials and Methods)
- Results
- Discussion
- Acknowledgments
- Supporting Information paragraph (if necessary)
- References
- Tables (must be included in the manuscript file, not uploaded separately)
- Structures, Charts, Schemes
- Figure Legends
- Figures
- Graphic for the Table of Contents
- Supporting Information (as a separate file)

Illustration Preparation

General Considerations. Remove all color from graphics, except for those graphics that you would like to have considered for publication in color (see Color section below for details). Insert your illustrations into the manuscript following the Web instructions for manuscript preparation. See <http://pubs.acs.org/page/4authors/submission/index.html> for additional guidance. The quality of the graphics in the Journal depends on the quality of the graphics provided by the author.

In addition to being embedded in the manuscript, graphics can be submitted individually. Acceptable file formats include TIFF, PDF, EPS (vector artwork), and CDX (ChemDraw). Individual graphics should be named on the basis of their function in the manuscript (i.e., Scheme 1, Figure 1, Chart 1, etc.). All parts of a figure should be assembled into a single graphic.

For EPS files, please ensure that all fonts are converted to outlines or embedded in the graphic. The document settings should be in RGB mode. Also, EPS vector-based graphics will be rasterized for production.

For TIFF files, please use the following resolutions: 1200 dpi for black and white line art, 600 dpi for grayscale art, and 300 dpi for color art. These resolutions and the RGB settings will ensure high-quality reproduction for publication. Graphics submitted in CMYK form or at lower resolutions can be used but might result in inconsistent colors and poor quality that might not be correctable.

Figures cannot be modified or enhanced by the journal production staff.

Illustrations must fit a one- or two-column format on the journal page: **For efficient use of journal space, single column illustrations are preferred.**

	single (preferred)	double
width		
minimum		10.6 cm (4.167 in.)
maximum	8.5 cm (3.33 in.)	17.8 cm (7 in.)
maximum depth	23.3 cm (9.167 in.)	23.3 cm (9.167 in.)

For the final revision, illustrations should be submitted in the actual size at which they should appear in the Journal. Illustrations which do not need to be reduced to fit a single- or double-column format will yield the best quality. Lettering should be no smaller than 4.5 points. (Helvetica or Arial type works well for lettering.) Lines should be no thinner than 0.5 point. Lettering and lines should be of uniform density.

If your artwork must be reduced, use larger lettering and thicker lines so that, when reduced, the artwork meets the above-mentioned parameters.

Avoid using complex textures and shading to achieve a three-dimensional effect. To show a pattern, choose a simple cross-hatch design.

Color. Color graphics may be published in the Journal if approved by the Editor. Color should be used only when essential for understanding the results presented. Do not submit color graphics to be published in black and white.

Chemical Structures. Structures should be produced with the use of a drawing program such as ChemDraw. Structure drawing preferences (preset in the ACS Stylesheet in ChemDraw) are as follows:

(1) As drawing settings select:

chain angle	120°
bond spacing	18% of width
fixed length	14.4 pt (0.508 cm, 0.2 in)
bold width	2.0 pt (0.071 cm, 0.0278 in)
line width	0.6 pt (0.021 cm, 0.0084 in)
margin width	1.6 pt (0.056 cm, 0.0222 in)
hash spacing	2.5 pt (0.088 cm, 0.0347 in)

(2) As text settings select:

font	Arial/Helvetica
size	10 pt

(3) Under the preferences choose:

units	points
tolerances	5 pixels

(4) Under page setup choose:

Paper	US Letter
Scale	100%

Authors using other drawing packages should, insofar as possible, modify their program's parameters so that they reflect the above guidelines.

Title Page (page 1). **A. Title.** Provide a brief and informative title to assist in the classification and indexing of the paper. Do not use trade names of drugs or abbreviations. Serial numbers may be used only if consecutive papers appear in the same issue of *Biochemistry*. Avoid uninformative titles such as "Studies on ...". **B. Funding Source Statement.** Give acknowledgments of financial aid, including the granting agency and the grant award identification number. The submitting author is asked to select funding sources from the list of agencies included in the FundRef Registry (<http://www.crossref.org/fundref/>). (Other acknowledgments should appear in a separate section at the end of the Discussion.) Identifying funding sources is optional during submission of an original manuscript. Funding source information is required when a revised manuscript is submitted. **C. Byline.** List full names and institutional affiliations of all authors. It is implicit in listing a person as an author that he/she has agreed to co-author the manuscript and is in full agreement with its content. The symbol * should be used to indicate the author to whom correspondence should be addressed. Provide complete contact information for the corresponding author, including a phone number and an e-mail address.

Abbreviations and Textual Footnotes (page 2). List the abbreviations used in an individual paragraph. Textual footnotes, numbered consecutively, should be brief and kept to a minimum.

Abstract (page 3). An abstract of not more than 250 words should succinctly present the problem and experimental approach and state major findings and conclusions. It should be self-explanatory and suitable for reproduction by abstractive services without rewriting. Since the abstract will be published in Chemical Abstracts, footnotes or undefined abbreviations may not be used. If a reference must be cited, complete publication data must be given [e.g., White, R. H. (1982) *Biochemistry* 21, 4271–4275].

Introduction (no heading, page 4). The introduction should state the purpose of the investigation and its relationship to other work in the field. Extensive reviews of the literature should be avoided.

Experimental Procedures (Materials and Methods). The materials should be described in sufficient detail to enable others to repeat the experiments. Names of products and manufacturers should be included only if alternate sources are deemed unsatisfactory. Novel experimental procedures should be described in detail, but published procedures should merely be referred to by literature citation of both the original and any published modifications. In submitting a manuscript to *Biochemistry*, authors agree to make available to interested academic researchers for their own use any materials reported in their manuscript that are not otherwise obtainable. Such requests should respect the purpose for which an author has prepared the materials being requested in order to avoid conflicts of competition with the originating laboratory.

Hazardous Procedures. Whenever hazardous materials or dangerous procedures are utilized, the necessary precautions should be stated.

Results. The results should be presented concisely. Tables and figures should be used only if they are essential for the comprehension of the data. The same data should not be presented in more than one figure or in both a figure and a table. As a rule, interpretation of the results should be reserved for the Discussion. In the interest of economy of space, Supporting Information (also subject to review) should be submitted as a separate file. The policy of the Journal is to publish only representative data. For example, routine gels and linear plots will not be published. However, if such information is important for evaluating the research, it should be included in the submission for the reviewers or as Supporting Information. The Supporting Information will be included in the web edition of the Journal (see Supporting Information).

Kinetic and Equilibrium Data. Authors are referred to the STREND A (Standards for Reporting Enzymology Data) Commission of the Beilstein Institut (<http://www.strenda.org/documents.html>) for an example of detailed guidelines. For publication in *Biochemistry*, the reporting of steady-state, pre-steady-state, or approach-to-equilibrium kinetic data and equilibrium-binding data for proteins, nucleic acids, and other species must include a description of the identity of the catalyst or binding molecule, its origin, purity of composition, and any modifications such as mutations, post-translational modifications, or other modifications made to facilitate expression and purification. The method of assay and the exact experimental conditions of the assay must be provided as a reference to previous work, with or without modifications, or fully described if a new assay. Regardless of whether previously reported, the temperature, pH, and pressure (if other than atmospheric) of the assay **must** be included. Terms such as “not detectable” (ND) should be avoided. Instead, an estimate of the limit of detection based on the sensitivity and error analysis of the assay should be provided.

First-order and second-order rate constants (including steady-state values of k_{cat} and $k_{\text{cat}}/K_{\text{M}}$ for enzymes and nucleic acids) should be reported in units of s^{-1} and $\text{M}^{-1} \text{s}^{-1}$, respectively. Equilibrium binding constants should normally be reported as dissociation constants with units of concentration (M, mM, μM , etc.). Steady-state enzyme activity (specific activity) should be optimally reported as k_{cat} or, if there is uncertainty in the molar concentration of the catalyst, as a V_{max} (nmol, μmol) of product formed per amount of protein per unit time. All reported parameters should be given with a calculated estimate of error and a description of the software used in the data analysis.

Protein Sequence Data. These data should be deposited with **Protein Identification Resource, National Biomedical Research Foundation, Georgetown University Medical Center, Washington, DC 20007**. For the documentation of the sequence analysis of proteins, see *Biochemistry* (1983) 22, 2595. Authors of accepted papers containing nucleotide sequences should submit the sequence data, preferably in computer-readable form, plus information for annotation of the data and a copy of the paper to **GenBank Submissions, National Center for Biotechnology Information (NCBI), Building 38A, Room 8N-805, 8600 Rockville Pike, Bethesda, Maryland 20894** [telephone (301) 496-2475; fax (301) 480-9241; e-mail (submissions) gbsub@ncbi.nlm.nih.gov, (information) info@ncbi.nlm.nih.gov]. Submission to

GenBank ensures entry also into the Protein Data Bank in Europe (PDBe). A separate paragraph should indicate that such a deposit has been made.

Manuscripts dealing primarily with the isolation, sequencing, and expression of DNA segments usually are not appropriate for *Biochemistry* unless significant new information is obtained about the structure and/or function of the proteins. Also, manuscripts primarily dealing with protein-sequence comparisons and evolutionary considerations are appropriate only if they explain important results not previously understood or make important predictions that can be experimentally tested.

Structural Data. For papers describing structures of biological macromolecules, the atomic coordinates and the related experimental data (structure factor amplitudes/intensities and/or NMR restraints) must be deposited at a member site of the Worldwide Protein Data Bank (www.wwpdb.org): RCSB PDB (www.pdb.org), PDBe (www.ebi.ac.uk/pdbe), PDBj (www.pdbj.org), or BMRB (www.bmrwisc.edu). The PDB ID should be included in the manuscript. Authors must agree to release the atomic coordinates and experimental data when the associated article is published. Questions relating to depositions should be sent to deposit@wwpdb.org. A manuscript will be accepted only after receipt from the submitting author of a written statement that the coordinates have been deposited. Coordinates must be released immediately upon publication.

Manuscripts that report X-ray crystallographic structures should include a table of data statistics that contains the number of reflections, data cutoff (e.g., $F > 0$), $R_{\text{work}}/R_{\text{free}}$, $\langle \sigma(I) \rangle$, percent completeness, redundancy, R_{merge} , number of atoms per asymmetric unit, and B -factors for protein, waters, and ligands/ions. Please address all inquiries about deposition to the Protein Data Bank. For papers that involve NMR studies in which complete or nearly complete resonance assignments of biopolymers have been carried out, authors are required to deposit relevant NMR assignments and related experimental data at the BioMagResBank (BMRB; <http://www.bmrwisc.edu>). These data may include assigned chemical shifts, coupling constants, relaxation parameters (T_1 , T_2 , and NOE values), dipolar couplings, or other data accepted by BMRB. The author is responsible for obtaining a BMRB entry accession number (i.e., 4238), which should appear in a data deposition paragraph. The data must be released upon publication.

Crystal structures of nucleic acids should be deposited with the **Nucleic Acid Database (NDB; <http://ndbserver.rutgers.edu/>; ndbadmin@ndbserver.rutgers.edu)** at <http://ndbserver.rutgers.edu/NDB/deposition/> or with the RCSB PDB at <http://pdb.rutgers.edu/adit/>. A preprint of the related manuscript should be mailed or faxed to **The Nucleic Acid Database, Department of Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, New Jersey 08854-8087 [fax (732) 445-4320]**.

For papers describing structures of biological macromolecules from electron microscopy experiments, the 3D map should be deposited at either the Protein Data Bank in Europe (UK) or RCSB (USA) EMDB deposition site (<http://www.emdatabank.org/>). Once the map has been deposited, any fitted atomic coordinates should be deposited with the Protein Data Bank (PDB) by following the link provided from the EMDB deposition

session. The EMDb and PDB IDs should be included in the manuscript. Both the map and the coordinate data will be made public when the associated article is published.

Manuscripts dealing with the development of structures from sequence homology are generally not considered unless significant experimental tests of the model also are presented.

Circular Dichroism Data. For papers including circular dichroism spectra of proteins, we encourage authors to deposit the raw, processed, and metadata in the Protein Circular Dichroism Data Bank (PCDDb) located at <http://pcddb.cryst.bbk.ac.uk> prior to submission of the manuscript and to include the PCDDb ID in the manuscript.

Other Databases. Authors may wish to submit binding constants and associated information to the public database BindingDB (www.bindingdb.org).

Discussion. The purpose of the discussion is to interpret the results and to relate them to existing knowledge in the field. In general, observe the utmost brevity consistent with clarity and avoid personal polemics. Information given elsewhere in the manuscript should not be repeated in the Discussion. Exhaustive reviews of the literature should be avoided.

Acknowledgment. Acknowledgments in this section should include technical assistance, advice from colleagues, gifts, etc. Prior permission must be obtained from persons whose contribution to the work is acknowledged in the manuscript. (Financial support should be acknowledged in the Funding Source Statement on the title page.)

Appendix. An appendix contains necessary background information not included in the text. Its use is optional.

References. References should clearly identify the original contributor to the work being cited. The number of references should be appropriate for the scope of the work. Excessive references should be avoided. The accuracy of the references is the responsibility of the author. Because subscribers to the Web edition of the Journal are now able to click on the "CAS" tag following each reference to retrieve the corresponding CAS abstract, reference accuracy is critical. **Textual references should be cited by superscript number in order of appearance. Citations in the reference list at the end of the manuscript should be arranged and numbered (1., 2., etc.) in order of appearance.** Please follow the punctuation pattern given in these examples: Wegner, A. (1979) Equilibrium study of the actin–tropomyosin interaction, *J. Mol. Biol.* 131, 839–853. Kossiakoff, A. A., and Spencer, S. A. (1981) Direct determination of the protonation states of aspartic acid-102 and histidine-57 in the tetrahedral intermediate of the serine proteases: neutron structure of trypsin, *Biochemistry* 20, 6462–6474. Johnson, G. L., Mac Andrew, V. I., and Pilch, P. F. (1981) Identification of the glucagon receptor in rat liver membranes by photoaffinity cross-linking, *Proc. Natl. Acad. Sci. U.S.A.* 78, 875–878. All references must include the complete title and inclusive pagination. Titles of journals are abbreviated according to *Chemical Abstracts Service Source Index*. Serial publications such as *Advances in Protein Chemistry*, *Methods in Enzymology*, and *The Proteins* should be listed in the same form as journals. References to chapters and monographs are listed as follows: Fierke, C. A., and

Hammes, G. G. (1996) Transient Kinetic Approaches to Enzyme Mechanisms, in *Contemporary Enzyme Kinetics and Mechanism* (Purich, D., Ed.) 2nd ed., pp 1–35, Academic Press, New York. Cite papers that have been accepted for publication as in press and supply their DOI numbers whenever possible. Papers that are in preparation or have been submitted but not yet accepted should be cited in the text as unpublished experiments or personal communications. The author must obtain written permission to cite unpublished work of others or to use material taken directly from a copyrighted publication.

Provide complete numbers in the page ranges; e.g., 1234-1237, not 1234-7.

Tables. Use tables only when the data cannot be presented clearly otherwise. Tables should be numbered consecutively with Arabic numerals. Provide a brief title for each table and a brief heading for each column. Clearly indicate the units of measure (preferably SI). Data should be rounded to the nearest significant figure. Give standard deviations if appropriate. Explanatory material referring to the whole table is to be included as a footnote to the title. Table footnotes are always identified by superscript letters, lowercase and italicized. All tables and figures should be cited in the text. All tables must be included in the source manuscript file and not uploaded separately as graphics.

Structures, Charts, and Schemes. High-resolution electronic versions with all components intact should be submitted within the manuscript file. Each chart and scheme should be on a separate page.

Figure Legends. The legend should include the figure number and a brief description, preferably one or two sentences or descriptive phrases. It should be understandable without reference to the text and should not include new material that is not in the text. Explain all symbols and abbreviations used in the illustrations. Simple symbols such as O, 9, and 4 should be used. The use of error bars on the data points is recommended. Figure legends must be included in the manuscript source file.

Figures. Figures should be kept to a minimum and should be used only to document experimental results or methods that cannot be adequately described in the text. The same data should not be presented in more than one figure or in a figure and table(s). Simple linear plots (e.g., double-reciprocal kinetic plots or calibration curves for the determination of molecular weights) that can be easily described in the text should be avoided. Diagrams of amino acid sequences should be prepared for efficient utilization of space. When three-letter abbreviations are used, for reduction to single-column width, each line should contain symbols for 15 amino acids, each symbol separated from the next by a hyphen (or comma when applicable). For double-column presentation, each line should contain three-letter symbols for 30 amino acid residues. For the presentation of extended protein sequences, one-letter abbreviations of amino acid residues should be used.

Stereo diagrams should be submitted so that they can be reproduced in full size, with the interocular distance between similar points on the original being between 5.5 and 6.5 cm. Defocused representations are preferred, and the representation used should be stated in the legend. Symbols, letters, and numbers should be large enough to be

readable after reduction of the graphs to single-column width. Please indicate if an illustration requires special treatment in order to show essential details that would not be reproduced well on regular stock.

Graphic for the Table of Contents (ToC Graphic). This illustration should capture the reader's attention and, in conjunction with the manuscript title, should give the reader a quick visual impression of the essence of the paper without providing specific results. The graphic should be in the form of a structure, graph, drawing, electrophoresis gel, or reaction scheme. Authors must submit a graphic in the actual size to be used for the table of contents (TOC) that will fit in an area 1.375 in. high and 3.5 in. wide (3.5 cm × 8.9 cm). Larger images will be reduced to fit within those dimensions. Type size of labels, formulas, or numbers within the graphic must be legible. Tables or spectra are not acceptable. Color is encouraged. Authors must provide the TOC graphic upon submission of the paper as the last page of the manuscript. Authors should label this page "For Table of Contents Use Only" and include the manuscript title and authors.

Supporting Information. The nature of the material should be indicated in a paragraph in the text, to follow the Acknowledgment, as follows: "Supporting Information Available" followed by a brief statement in nonsentence format listing the contents of the material supplied as Supporting Information. Figures and tables in the supplement should be numbered consecutively but independently of those in the body of the manuscript (e.g., Fig. S1). Animated videos can be submitted for the online version of Biochemistry. Supporting Information must be submitted at the same time as the manuscript and uploaded separately to the ACS Paragon Plus Environment. A [list of acceptable file types](#) is available on the Web. All Supporting Information files of the same type should be prepared as a single file (rather than submitting a series of files containing individual images or structures). For example, all Supporting Information available as PDF files should be contained in one PDF file.

DO NOT UPLOAD FIGURES AND TABLES THAT ARE TO BE PUBLISHED IN THE ARTICLE INTO THE SUPPORTING INFORMATION FILE.

ACCEPTED PAPERS

Proofs

Correction of galley proofs is the responsibility of the corresponding author. The corresponding author of an accepted manuscript will receive e-mail notification and complete instructions when page proofs are available for review via a secure Web site. Authors will access the secure site through ACS ChemWorx and will need an ACS ID. To obtain an ACS ID or to reset your password, go to <http://www.acschemworx.acs.org>. Routine rephrasing of sentences or additions are not permitted at the page-proof stage. Alterations should be restricted to serious changes in interpretation or corrections of data. Extensive or important changes on page proofs, including changes to the title or list of authors, are subject to Editorial review. It is the responsibility of the corresponding author to ensure that all authors listed on the manuscript agree with the changes made on the proofs. Galley proofs should be returned within 48 hours of receipt in order to ensure timely publication of the manuscript.

ACS Policies for E-prints and Reprints

Under the [ACS Articles on Request policy](#), the Society will provide (free of charge) to all contributing authors a unique URL within the ACS website that they may e-mail to colleagues or post on external websites. These author-directed links are designed to facilitate distribution of an author's published work to interested colleagues in lieu of direct distribution of the PDF file by the author. The ACS Articles on Request policy allows 50 downloads within the first year after publication and unlimited access via the same author-directed links 12 months after publication.

Upon receipt of the proof of their paper, authors will receive a link to a website where they may order author reprints. They may also call Cierant Corporation at (866) 305-0111 from 9AM to 5PM EST. Reprints will be shipped within two weeks after the issue publication date. Neither the Editors nor the Washington ACS Office keeps a supply of reprints; requests for single copies of papers should be addressed to the corresponding author of the paper concerned.

ACS AuthorChoice Open Access

[ACS AuthorChoice](#) options establish fee-based mechanisms for authors or their research funding agencies to sponsor the open availability of final published articles on the Web. ACS AuthorChoice offers authors a wide range of open access license options, such as Creative Commons licenses and provisions for immediate or 12-month embargoed open access, and includes [ACS Certified Deposit](#). Authors will find useful information about compliance with open access policies available [here](#) and FAQs [here](#). Corresponding authors who published with ACS during 2014 may have access to [ACS Author Rewards](#), a \$60M stimulus program ACS provided to help authors transition to new open access publishing models.

Authors must sign the Journals Publishing Agreement. Forms and complete instructions are available [here](#). After acceptance, authors will be presented with the opportunity to purchase an ACS AuthorChoice option, and authors who do so will be presented with the appropriate license at that time. For a review of all license options available, see [here](#). For questions or further assistance with ACS AuthorChoice, please reach out to support@services.acs.org.